ClinicalTrials.Veeva

Menu

Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

B

Beijing Tsinghua Chang Gung Hospital

Status

Unknown

Conditions

Fatty Liver Disease

Treatments

Diagnostic Test: Fibrotouch

Study type

Observational

Funder types

Other

Identifiers

NCT05421572
CG-MAFLD-001

Details and patient eligibility

About

To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China

Full description

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.

Enrollment

2,000 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Aged between 18 and 75, both sex;
  • Able to sign informed consent.

Exclusion criteria

  • Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.

Trial design

2,000 participants in 1 patient group

Single Group Assignment
Description:
Adults with health check-ups at multiple health examination centers across China
Treatment:
Diagnostic Test: Fibrotouch

Trial contacts and locations

1

Loading...

Central trial contact

Ming Yang, MD; Lai Wei, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems